Starpax Biopharma appoints Vice President Finance
by CM staff
The appointment is effective as of January 3, 2024.
(CNW Group/Starpax Biopharma Inc.)
MONTREAL — Starpax Biopharma Inc., a biopharmaceutical company developing a cancer treatment platform technology (Starpax), announced the promotion of Andréanne Cyr to Vice President Finance. This appointment is effective as of January 3, 2024.
Andréanne Cyr is a Certified Public Accountant (CPA) with 10 years of experience in finance, holding positions as auditor and director of finance in various industries. She has worked for several years at Grant Thornton Montréal as a director on audit files for public companies, insurance companies as well as international audit files.
Cyr joined the company in 2022. Since joining the company, she has held responsibilities in the areas of financial reporting, taxation, finance and public filings at the security and exchange commission of the U.S., notably in respect of Starpax recent qualification of its exempt offering under Regulation A+ of the SEC.
“These strategic nominations were planned with our current CFO, Jean François Pruneau, who during his two-year mandate completed the setting up and structuration of Starpax’ corporate finance function. We are now ready to move to the next level with the beginning in 2024 of our clinical trials on humans, our intent to launch an Initial Public Offering and planning the future commercial launch of the Starpax technology,” said Michael Gareau, founding president of Starpax Biopharma.
Jean-Francois Pruneau is a shareholder of Starpax and will continue to advise, from time to time, the company as a shareholder. He will leave Starpax effective January 8, 2024.
